Tumor-associated self-antigen peptide–MHC class II complex (pMHC II) (pMHC II)

The tumor-associated self-antigen peptide–MHC class II complex is a molecular assembly consisting of a peptide fragment derived from a tumor-associated antigen (TAA) bound within the groove of a Major Histocompatibility Complex (MHC) class II molecule. While MHC class II is primarily expressed on professional antigen-presenting cells like dendritic cells and B cells, it can also be induced on various tumor cells, particularly in response to inflammatory cytokines like interferon-gamma (Source: PubMed, PMID: 31435457). These complexes are essential for the activation of CD4+ T helper cells, which provide critical help for CD8+ cytotoxic T cell responses and can also exert direct anti-tumor effects (Source: Nature Reviews Cancer, 2019). In the context of immunotherapy, these complexes serve as highly specific targets for TCR-like antibodies and engineered T-cell therapies, allowing the immune system to distinguish between malignant and healthy cells based on intracellular protein expression (Source: Journal of Hematology & Oncology, 2020). However, because these antigens are self-derived, therapeutic strategies must carefully manage the risk of autoimmunity and off-target effects on healthy tissues that may express low levels of the target antigen (Source: Frontiers in Immunology, 2019). The density of these complexes on the cell surface is often a limiting factor for therapeutic efficacy, necessitating the development of high-affinity binding agents to ensure robust immune activation (Source: NIH, 2022). Furthermore, the heterogeneity of MHC expression and peptide presentation across different tumor regions presents a significant challenge for achieving consistent therapeutic outcomes (Source: PubMed, PMID: 32165432).

Other names

Tumor-associated self antigen peptide–MHC class II complexes on tumor cells and antigen-presenting cellsTumor-associated antigen peptide-MHC II complexpMHCIIMHC class II-restricted tumor antigenHLA class II-peptide complexTASA-MHC II complex

Drugs targeting these complexes typically function by mimicking the natural T-cell receptor (TCR) recognition mechanism, leading to the recruitment and activation of immune effector cells or the delivery of cytotoxic payloads directly to the tumor cell (Source: Journal of Hematology & Oncology, 2020).